Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma
Lung adenocarcinoma (LUAD) is one of the most prevalent pathological kinds of lung cancer, which is a common form of cancer that has a high death rate. Over the past several years, growing studies have indicated that GPD1L was involved in the advancement of a number of different cancers. However, it...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2023/9162249 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547972234084352 |
|---|---|
| author | Zhengyang Fan Song Wu Hongyang Sang Qianping Li Shaofei Cheng Hongling Zhu |
| author_facet | Zhengyang Fan Song Wu Hongyang Sang Qianping Li Shaofei Cheng Hongling Zhu |
| author_sort | Zhengyang Fan |
| collection | DOAJ |
| description | Lung adenocarcinoma (LUAD) is one of the most prevalent pathological kinds of lung cancer, which is a common form of cancer that has a high death rate. Over the past several years, growing studies have indicated that GPD1L was involved in the advancement of a number of different cancers. However, its clinical significance in LUAD has not been investigated. In this study, following an examination of the TGCA datasets, we found that GPD1L displayed a dysregulated state in a wide variety of cancers; this led us to believe that GPD1L is an essential regulator in the progression of malignancies. In addition, we found that the expression of GPD1L was much lower in LUAD tissues when compared with nontumor specimens. According to the findings of ROC tests, GPD1L was able to effectively identify LUAD specimens from nontumor samples with an AUC value of 0.828 (95% confidence interval: 0.793 to 0.863). On the basis of the clinical study, a low expression of GPD1L was clearly related with both the N stage and the clinical stage. Moreover, based on the findings of a Kaplan-Meier survival study, elevated GPD1L expression was a strong indicator of considerably improved overall survival (OS) and disease-specific survival (DSS). GPD1L expression and clinical stages were found to be independent prognostic indicators for overall survival and disease-free survival in LUAD patients, according to multivariate analyses. Based on multivariate analysis, the C-indexes and calibration plots of the nomogram demonstrated an effective prediction performance for LUAD patients. Besides, the expression of GPD1L was positively related to mast cells, eosinophils, Tcm, TFH, iDC, DC, and macrophages, while negatively associated with Th2 cells, NK CD56dim cells, Tgd, Treg, and neutrophils. Finally, qRT-PCR was able to demonstrate that GPD1L had a significant amount of expression in LUAD. Additionally, according to the results of functional tests, overexpression of GPD1L had a significant inhibiting effect on the proliferation of LUAD cells. In general, the results of our study suggested that GPD1L had the potential to serve as a diagnostic and prognostic marker for LUAD. |
| format | Article |
| id | doaj-art-2b74a66c864e4b189b73bfb0391b61bb |
| institution | Kabale University |
| issn | 1466-1861 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-2b74a66c864e4b189b73bfb0391b61bb2025-02-03T06:42:39ZengWileyMediators of Inflammation1466-18612023-01-01202310.1155/2023/9162249Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung AdenocarcinomaZhengyang Fan0Song Wu1Hongyang Sang2Qianping Li3Shaofei Cheng4Hongling Zhu5Department of Cardiothoracic SurgeryDepartment of Cardiothoracic SurgeryDepartment of Cardiothoracic SurgeryDepartment of Cardiothoracic SurgeryDepartment of Cardiothoracic SurgeryDepartment of OncologyLung adenocarcinoma (LUAD) is one of the most prevalent pathological kinds of lung cancer, which is a common form of cancer that has a high death rate. Over the past several years, growing studies have indicated that GPD1L was involved in the advancement of a number of different cancers. However, its clinical significance in LUAD has not been investigated. In this study, following an examination of the TGCA datasets, we found that GPD1L displayed a dysregulated state in a wide variety of cancers; this led us to believe that GPD1L is an essential regulator in the progression of malignancies. In addition, we found that the expression of GPD1L was much lower in LUAD tissues when compared with nontumor specimens. According to the findings of ROC tests, GPD1L was able to effectively identify LUAD specimens from nontumor samples with an AUC value of 0.828 (95% confidence interval: 0.793 to 0.863). On the basis of the clinical study, a low expression of GPD1L was clearly related with both the N stage and the clinical stage. Moreover, based on the findings of a Kaplan-Meier survival study, elevated GPD1L expression was a strong indicator of considerably improved overall survival (OS) and disease-specific survival (DSS). GPD1L expression and clinical stages were found to be independent prognostic indicators for overall survival and disease-free survival in LUAD patients, according to multivariate analyses. Based on multivariate analysis, the C-indexes and calibration plots of the nomogram demonstrated an effective prediction performance for LUAD patients. Besides, the expression of GPD1L was positively related to mast cells, eosinophils, Tcm, TFH, iDC, DC, and macrophages, while negatively associated with Th2 cells, NK CD56dim cells, Tgd, Treg, and neutrophils. Finally, qRT-PCR was able to demonstrate that GPD1L had a significant amount of expression in LUAD. Additionally, according to the results of functional tests, overexpression of GPD1L had a significant inhibiting effect on the proliferation of LUAD cells. In general, the results of our study suggested that GPD1L had the potential to serve as a diagnostic and prognostic marker for LUAD.http://dx.doi.org/10.1155/2023/9162249 |
| spellingShingle | Zhengyang Fan Song Wu Hongyang Sang Qianping Li Shaofei Cheng Hongling Zhu Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma Mediators of Inflammation |
| title | Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma |
| title_full | Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma |
| title_fullStr | Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma |
| title_full_unstemmed | Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma |
| title_short | Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma |
| title_sort | identification of gpd1l as a potential prognosis biomarker and associated with immune infiltrates in lung adenocarcinoma |
| url | http://dx.doi.org/10.1155/2023/9162249 |
| work_keys_str_mv | AT zhengyangfan identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma AT songwu identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma AT hongyangsang identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma AT qianpingli identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma AT shaofeicheng identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma AT honglingzhu identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma |